The 10-year exclusive agreement covers seven countries and includes an initial binding device order, a Brazilian clinical pilot and a framework for locally manufactured devices and recurring electrode royalties.
Key Investor Takeaways
- Nexalin Technology (NASDAQ:NXL) signed a definitive exclusive South America distribution agreement with Inovanexa Medical Technologies covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela.
- The agreement includes a binding initial purchase order for 10 Nexalin Sync devices, with five to be delivered immediately and a Brazilian clinical pilot targeted to begin within 90 days.
- An initial 100-device commercialization programme establishes pricing and provides a framework for larger government and private-sector transactions.
- After the first 30 devices are purchased, Inovanexa is required to establish Brazilian manufacturing at its own cost, while Nexalin receives per-device compensation and royalties on locally manufactured disposable electrodes.
- The agreement provides a potential route toward commercial revenue generation, although Nexalin cautioned that orders beyond the initial 10 devices and the broader commercial objectives are not guaranteed.
Why NXL Stock Is in Focus
Nexalin Technology has converted its earlier South American commercialization plans into a definitive distribution agreement, giving Inovanexa exclusive rights to market and sell the Nexalin Sync neurostimulation device across seven countries representing a combined population of more than 300 million.
The initial term is 10 years, with successive 10-year renewals dependent on performance. The agreement replaces the letter of intent signed by the companies in February 2026.
Commercial activity starts with a binding order for 10 devices. Five are due for immediate delivery, followed by deployment of the initial units through a Brazilian clinical pilot targeted for launch within 90 days.
The agreement also sets out pricing for the first 100 devices. Inovanexa can pursue private-sector customers as well as federal, state and municipal procurement opportunities, hospitals and universities.
Brazil provides the initial market because Nexalin Sync already has ANVISA approval for anxiety, depression and insomnia. Nexalin also previously completed a clinical trial at the University of São Paulo’s Institute of Psychiatry that reported a 77.8% anxiety response rate.
Why This Matters for Investors
The most immediate significance is the binding initial order, which provides a defined starting point for Nexalin’s stated transition toward commercial revenue generation in South America.
The longer-term economics may depend more heavily on whether Inovanexa progresses beyond those first devices. Once 30 units have been purchased, the distributor is required to establish local manufacturing in Brazil at its own expense and under Nexalin’s technical supervision.
That structure could limit Nexalin’s capital requirements while preserving several potential revenue channels. The company would retain its intellectual property, exclusively supply the encrypted circuit boards required for the devices, receive fixed compensation for locally manufactured units and collect per-unit royalties on disposable electrodes.
The disposable component could introduce a recurring, usage-linked revenue stream if the installed base expands. Qualifying private-sector transactions involving devices assembled in Brazil would also be subject to an equal profit-sharing arrangement.
However, the scale of that opportunity remains dependent on execution. Nexalin explicitly stated that there is no assurance Inovanexa will satisfy the agreement’s performance requirements, place orders beyond the initial commitment or achieve the planned commercial objectives.
What to Watch Next
The first milestones are delivery of the initial five devices and the targeted launch of the Brazilian clinical pilot within 90 days.
Beyond that, investors can watch for purchases reaching the 30-device threshold that triggers local manufacturing, progress toward the initial 100-device commercialization programme and any government or private-sector contracts.
Expansion of this distribution model into additional markets could also become relevant, while Nexalin continues its separate FDA De Novo pathway in the United States.